BiO2 Medical Enrolls Subjects in the New U.S. FDA Early Feasibility Pilot Study for the Angel® Catheter
BiO2 Medical, Inc. is proud to announce the Angel® Catheter Early Feasibility Clinical Study has enrolled its first 3 subjects. Research teams led by Dr. John Holcomb at University of Texas, Houston(Memorial Hermann Hospital) and Dr. Larry Martin at University of Mississippi, Jackson participated in these cases with the first ...
BiO2 Medical announces approval of an IDE to initiate a clinical investigation of the Angel® Catheter for Pulmonary Embolism (PE) protection. The study, entitled The Angel® Catheter Clinical Trial: Prevention of Pulmonary Embolism in High Risk Subjects, will build on the positive results of a ...
Enrollment for The Angel Catheter® Clinical Trial has begun with three patients successfully enrolled. Site Initiation Visits are underway with a goal to include up to 30 U.S. sites in this multicenter, prospective, single arm clinical investigation of the Angel® Catheter. At the successful completion ...
BiO2 Medical Executes Full Commercialization in the United Kingdom Partnering with United Drug Medical (UDM) as an Exclusive Distributor for the Angel® Catheter
BiO2 Medical, Inc., a Texas based medical device manufacturer with corporate offices in San Antonio, Texas, and R&D and manufacturing operations in Golden, Colorado, has signed a distribution agreement with Pyramed, a division of United Drug Medical (UDM). This milestone accomplishment grants Pyramed exclusive rights to distribute the Angel® Catheter throughout ...